Novartis Ag (NVSEF) SEC Filings — 2025
14 SEC filings for Novartis Ag (NVSEF) in 2025.
Filings
- Novartis Ag 6-K Filing — 6-K · Nov 25, 2025
- Novartis Projects 5-6% Sales CAGR 2025-2030 — 6-K · Nov 20, 2025
- Novartis Issues Over $5 Billion in Notes — 6-K · Nov 5, 2025
- Novartis AG Files Q3 2025 Financial Report on Form 6-K — 6-K · Oct 28, 2025
- Novartis to Acquire RNA Therapeutics Innovator Avidity Biosciences — 6-K · Oct 27, 2025
- FDA Approves Novartis' Rhapsido for Chronic Spontaneous Urticaria — 6-K · Sep 30, 2025
- Novartis ianalumab trials meet Sjögren's disease endpoints — 6-K · Aug 11, 2025
- Novartis AG Files Q2 2025 Financial Report — 6-K · Jul 17, 2025
- Novartis Appoints Mukul Mehta as New CFO, Harry Kirsch Retires — 6-K · Jul 17, 2025
- Novartis Pluvicto Shows Strong Prostate Cancer Benefit — 6-K · Jun 2, 2025
- Novartis AG Files Q1 2025 Financial Report — 6-K · Apr 29, 2025
- Novartis Vanrafia® Gets FDA Accelerated Approval for IgAN — 6-K · Apr 3, 2025
- FDA OKs Earlier Pluvicto Use for Prostate Cancer — 6-K · Mar 28, 2025
- Novartis AG Files 2024 Annual Report — 20-F · Jan 31, 2025